Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Gliosarcoma × Immunotherapy, Adoptive × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Glioma 4 Glioblastoma 2 Brain Neoplasms 2 Stomach Neoplasms 1 Sarcoma, Synovial 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Recurrence 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neuroblastoma 1 Neoplasms 1 Multiple Myeloma 1 Mesothelioma 1 Meningeal Carcinomatosis 1 Melanoma 1 Lymphoma, Follicular 1 Lymphoma 1 Lung Neoplasms 1 Leukemia, Myeloid 1 Gliosarcoma 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Burkitt Lymphoma 1 Breast Neoplasms 1 Astrocytoma 1

Interventions

Temozolomide 120 Radiotherapy 80 Bevacizumab 41 Radiation 29 Carmustine 26 Irinotecan 21 Erlotinib Hydrochloride 21 Magnetic Resonance Spectroscopy 18 Chemotherapy, Adjuvant 17 Surgical Procedures, Operative 13 O(6)-benzylguanine 13 Carboplatin 13 sargramostim 12 Radiotherapy, Intensity-Modulated 11 Radiotherapy, Conformal 11 Imatinib Mesylate 9 Thalidomide 8 motexafin gadolinium 7 Radiosurgery 7 Procarbazine 7 Gene Expression Profiling 7 Gefitinib 7 Filgrastim 7 Drug Therapy 7 Cyclophosphamide 7 pembrolizumab 6 cediranib 6 Vorinostat 6 Sirolimus 6 Lomustine 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02664363 2023-02-17

ExCeL

Duke University

Phase 1 Terminated

3 enrolled 8 charts

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡